Alzheimer's Disease Drug Development Program (U01)
Funding Number: PAR-12-015 Funding Type: PAR Release Date:November 16, 2011 Expiration Date:January 8, 2015 Web Site:http://grants.nih.gov/grants/guide/pa-files/PAR-12-015.html
The goal of this funding opportunity announcement (FOA) is to support pre-clinical development of new therapies aimed at modifying the behavioral symptoms in Alzheimer's disease (AD); or delaying the onset or slowing the progression of AD, mild cognitive impairment (MCI), or age-related cognitive decline. This program is specifically directed at projects focused on the optimization of therapeutic leads with demonstrated activity against an intended disease target. Projects must be sufficiently advanced that an IND or IDE application to the FDA can be submitted by the end of the funding period. The program does not support early-stage therapeutic discovery activities such as high throughput screening. The program also excludes clinical research and basic, mechanistic research. This is a milestone-driven cooperative agreement program involving participation of NIA program staff both in the development of the project plan and monitoring of research progress.